Before AlphaFold 3, drug designers had to rely on intuition and lengthy lab processes to understand molecular interactions, which is no longer the case.

AlphaFold 3 enables drug designers to model not just protein structures but also how these proteins interact with small molecules, enhancing our ability to design effective drugs.

AlphaFold 3 allows our drug designers to see how their molecule designs interact with protein targets instantly, which is a game changer in drug design.

The first generation of AI applications in drug design often focused on local models, but our approach is to build a more comprehensive system that can generalize across various tasks, as demonstrated by AlphaFold 3, which allows us to create models that generalize across chemistry and target space, enabling application to any protein or small molecule without needing fine-tuning.

Building a diverse team of experts in AI, chemistry, and biology is essential for questioning traditional approaches and fostering innovation in drug design.

Drug design is complex, with numerous bottlenecks before reaching clinical trials, and we need to innovate in this space to improve the process.

Our sister company, Isomorphic Labs, is developing technologies around AlphaFold to design drug compounds that bind to specific parts of protein surfaces, which is crucial for understanding diseases.

The advancements in AI, such as AlphaFold, are revolutionizing fields like medicine, enabling us to design proteins that can potentially cure diseases like cancer.

The intersection of drug design and machine learning is a new field, and we need to bring together experts from both areas to drive breakthroughs.